+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Testing/Screening Market - Forecast (2020 - 2025)

  • ID: 3753997
  • Report
  • March 2020
  • Region: Global
  • 112 pages
  • IndustryARC
1 of 3
Cancer Testing/Screening Market Overview:

According to the findings by WHO, the global mortality rate due to cancer in 2018 surged to 9.6 million. The same study states that up to an astonishing 50% of cancer cases could have been prevented with effective and inexpensive programmes in initial diagnosis, screening, treatment, and palliative care. With the annual economic burden of cancer well-exceeding US$1.16 trillion, the demand for medical facilities to detect and control this intricate disease at the earliest is surfacing the global healthcare forum. Owing to this demand, the global cancer testing market or cancer screening market size is estimated to be $123 billion-$133 billion as of 2018 and is growing at a global CAGR of 4.5%-5.5% during the forecast period 2019-2025.

Cancer Testing Market Outlook:

Cancer testing or screening plays an important role in the detection of various types of cancer before the appearance of symptoms. The main aim of cancer testing is to reduce the number of deaths caused by cancer.  Early diagnosis can lead to better treatment and a greater lifespan. Some of the cancer prevention testing-screening tests include various medical imaging tests, screening mammography, endoscopy tests, and biopsy tests.

After an acute analysis of the regional market segments, the Americas is figured to be the leading region, encapsulating nearly 50%-55% of the global cancer testing market demand. The sheer affluence can be explained by the fact that alone in the United States, the number of cancer cases registered in 2018 was estimated to be 1,735,350 (1.7 million).[2]  Similarly, the Canadian Cancer Society states that about 1 in 2 Canadians will develop cancer in their lifetimes and 1 in 4 will die of the disease.[3]  Cancer screening-testing being an expensive medical procedure has found the scope of application in high-income countries only as of right now. However, government support and indigenous technologies from countries such China, India, and Japan is helping the market penetration and mass commercialization. The majority of low-income economies with inaccessible diagnosis and treatment facilities stands out as potential spots to be capitalized upon by the cancer-screening testing market players.

Cancer Screening Market Growth Drivers and Trends:

‘Liquid biopsy’ is one of the latest technology emerging in the market which would help in early detection of various cancers by scanning for DNA fragments which are shed by tumor cells. Companies such SRBI healthcare, GRAIL Inc., and others are raising funds for early diagnosis of cancer.

In recent years, Next Generation Sequencing (NGS) is being widely used for the detection of various types of cancer. NGS allows simultaneous sequencing of targeted genomic areas in multiple samples to detect mutations. The main advantage of this method is the need of low amount of DNA or RNA.

Swiss startup SOPHiA Genetics has used Artificial Intelligence (AI) that takes raw genome data and studies the molecular profile of a person’s cancer to find more personalized treatment options. This technology helps the doctors to understand the cause of cancer and what best treatment can be suggested for the molecular events that are taking place in the body. It is also predicted that AI would be the future of cancer diagnostics.

Research and campaigns run by several organization regarding timely screening and cancer diagnosis are also disrupting the cancer-testing marketplace and progressing it towards broader commercialization. For example- Centers for Disease Control and Prevention campaign ‘Screen for Life’. American Cancer Society in 2017 invested $145 million in cancer research, $129 million in prevention information, and $80 million in detection.

Cancer Testing Market

Cancer Screening Market Players Perspective:

Some of the major key players operating in this technological novel and advanced healthcare landscape are Dias Orin S.P.A, Epigenetics Ag, Techlab, Genextropy Inc.,  M Genomics Ltd, 20/20 GeneSystems, Inc., AB SCIEX, Abbott Laboratories, Abcodia Ltd., and Abingdon Health Ltd.

Cancer Testing Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the cancer testing/screening market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnosis in cancer testing/screening market and their specific advantages.

Cancer Testing/Screening Market Report: Industry Coverage

By Cancer Type: Lung, Blood, Bone, Others

By Technique: Imaging, Endoscopy, Molecular & Genomics Testing

By Stage: TNM, Prognostic Factors, Others

The Cancer Testing/Screening Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

  • North America: The U.S., Canada, Mexico
  • South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica
  • Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark
  • APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong
  • Middle East and Africa: Israel, South Africa, Saudi Arabia

Key Questions Addressed in the Cancer Testing/Screening Market Report

  1. Is the market for cancer testing/screening growing? How long will it continue to grow and at what rate?
  2. Which type of systems presents the major growth opportunities?
  3. Is there a possibility for change in the market structure over time?
  4. Are additional developments needed for the existing product or services offerings or do the existing products meet the customer demands?
  5. Do the key vendors look for partnerships to expand their businesses with respect to geography or product?
  6. What are the short-term, long-term, and medium-term growth drivers for the market?
  7. What are the short-term, medium-term, and long-term challenges for the market?
  8. What are the short-term, medium-term, and long-term opportunities for the market
  9. Who are the top players/companies of the market?
  10. What are the recent innovations in the market?
  11. How many patents have been filed by the leading players?
  12. What are the types of patents filed by the leading players?
  13. What is our Vision 2030 for cancer testing/screening market?

A few focus points of this Research are given below:

  • Give a deep-dive analysis of the key operational strategies with focus on the corporate structure, R&D strategies, localization strategies, production capabilities, and sales performance of various companies
  • Provide an overview of the product portfolio, including product planning, development, and positioning
  • Discuss the role of technology companies in partnerships
  • Explore the regional sales activities
  • Analyze the market size and giving the forecast for current and future cancer testing/screening during the forecast 2019–2025
  • Analyze the competitive factors, competitors’ market shares, product capabilities, and supply chain structures.

Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Cancer Testing/Screening Market - Overview
1.1. Definitions and Scope

2. Cancer Testing/Screening Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography

3. Cancer Testing/Screening Market
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis

4. Cancer Testing/Screening Market Forces
4.1. Drivers
4.2. Constraints
4.3. Challenges
4.4. Porters five force model
4.4.1. Bargaining power of suppliers
4.4.2. Bargaining powers of customers
4.4.3. Threat of new entrants
4.4.4. Rivalry among existing players
4.4.5. Threat of substitutes

5. Cancer Testing/Screening Market -Strategic analysis
5.1. Value chain analysis
5.2. Opportunities analysis
5.3. Product life cycle
5.4. Suppliers and distributors Market Share

6. Cancer Testing/Screening Market – By Type (Market Size -$Million / $Billion)
6.1. Market Size and Market Share Analysis
6.2. Application Revenue and Trend Research
6.3. Product Segment Analysis
6.3.1. Introduction
6.3.2. Lung Cancer
6.3.3. Blood Cancer
6.3.4. Bone Cancer
6.3.5. Gall Bladder Cancer
6.3.6. Testicular Cancer
6.3.7. Thyroid Cancer
6.3.8. Kidney Cancer
6.3.9. Liver Cancer
6.3.10. Pancreatic Cancer
6.3.11. Brain Cancer
6.3.12. Abdominal Cancer
6.3.13. Eye Cancer
6.3.14. Mouth Cancer
6.3.15. Breast Cancer
6.3.16. Cervix Cancer
6.3.17. Ovarian Cancer
6.3.16. Others

7. Cancer Testing/Screening Market – By Technique (Market Size -$Million / $Billion)
7.1. Introduction
7.2. Imaging Techniques
7.2.1. CT scan
7.2.2. MRI
7.2.3. X-ray
7.2.4. Nuclear
7.2.5. Ultrasound
7.2.6. Mammography
7.2.7. Others
7.3. Endoscopy procedure
7.3.1. Colonoscopy
7.3.2. Sigmoidoscopy
7.3.3. Others
7.4. Biopsy and cytology tests
7.4.1. Needle biopsy
7.4.2. CT-guided biopsy
7.4.3. Ultrasound-guided biopsy
7.4.4. Bone biopsy
7.4.5.Bone marrow biopsy
7.4.6.Liver biopsy
7.4.7.Kidney biopsy
7.4.8. Aspiration biopsy
7.4.9. Prostate biopsy
7.4.10 Skin biopsy
7.4.11 Surgical biopsy
7.4.12 Others
7.5. Genomic and Molecular tests
7.5.1. Next Generation Sequencing (NGS)
7.5.2. RT- PCR
7.5.3. icroarray techniques
7.5.4. Biomarker testing
7.5.5. Others

8. Cancer Testing/Screening Market – By Stage (Market Size -$Million / $Billion)
8.1. TNM Stages
8.2. Stages 0,1,2,3,4
8.3. Prognostic Factors
8.4. Other Staging Systems

9. Cancer Testing/Screening Market – By Gender (Market Size -$Million / $Billion)
9.1. Men
9.1.1. New Born
9.1.2. Infant
9.1.3. Child
9.1.4. Adolescent
9.1.5. Adults
9.1.6. Seniors
9.2. Women
9.2.1. New Born
9.2.2. Infant
9.2.3. Child
9.2.4. Adolescent
9.2.5. Adults
9.2.6. Seniors

10. Cancer Testing/Screening - By Geography (Market Size -$Million / $Billion)
10.1. Cancer Testing/Screening Market - North America Segment Research
10.2. North America Market Research (Million / $Billion)
10.2.1. Segment type Size and Market Size Analysis
10.2.2. Revenue and Trends
10.2.3. Application Revenue and Trends by type of Application
10.2.4. Company Revenue and Product Analysis
10.2.5. North America Product type and Application Market Size
10.2.5.1. U.S.
10.2.5.2. Canada
10.2.5.3. Mexico
10.2.5.4. Rest of North America
10.3. Cancer Testing/Screening - South America Segment Research
10.4. South America Market Research (Market Size -$Million / $Billion)
10.4.1. Segment type Size and Market Size Analysis
10.4.2. Revenue and Trends
10.4.3. Application Revenue and Trends by type of Application
10.4.4. Company Revenue and Product Analysis
10.4.5. South America Product type and Application Market Size
10.4.5.1. Brazil
10.4.5.2. Venezuela
10.4.5.3. Argentina
10.4.5.4. Ecuador
10.4.5.5. Peru
10.4.5.6. Colombia
10.4.5.7. Costa Rica
10.4.5.8. Rest of South America
10.5. Cancer Testing/Screening - Europe Segment Research
10.6. Europe Market Research (Market Size -$Million / $Billion)
10.6.1. Segment type Size and Market Size Analysis
10.6.2. Revenue and Trends
10.6.3. Application Revenue and Trends by type of Application
10.6.4. Company Revenue and Product Analysis
10.6.5. Europe Segment Product type and Application Market Size
10.6.5.1. U.K
10.6.5.2. Germany
10.6.5.3. Italy
10.6.5.4. France
10.6.5.5. Netherlands
10.6.5.6. Belgium
10.6.5.7. Spain
10.6.5.8. Denmark
10.6.5.9. Rest of Europe
10.7. Cancer Testing/Screening – APAC Segment Research
10.8. APAC Market Research (Market Size -$Million / $Billion)
10.8.1. Segment type Size and Market Size Analysis
10.8.2. Revenue and Trends
10.8.3. Application Revenue and Trends by type of Application
10.8.4. Company Revenue and Product Analysis
10.8.5. APAC Segment – Product type and Application Market Size
10.8.5.1. China
10.8.5.2. Australia
10.8.5.3. Japan
10.8.5.4. South Korea
10.8.5.5. India
10.8.5.6. Taiwan
10.8.5.7. Malaysia

11. Cancer Testing/Screening Market - Entropy
11.1. New product launches
11.2. M&A's, collaborations, JVs and partnerships

12. Cancer Testing/Screening Market Company Analysis
12.1. Market Share, Company Revenue, Products, M&A, Developments
12.2. Dias Orin S.P.A
12.3. Epigenetics Ag
12.4. Techlab
12.5. Positive Bioscience
12.6. Genextropy Inc.
12.7. M Genomics Ltd
12.8. 20/20 GeneSystems, Inc.
12.9. AB SCIEX
12.10. Abbott Laboratories
12.11. Abcodia Ltd.

13. Cancer Testing/Screening Market -Appendix
13.1. Abbreviations
13.2. Sources
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

Loading
LOADING...

Adroll
adroll